Insilico Medicine names a potential first-class preclinical candidate with a novel AI-designed structure for a novel target discovered by AI in immuno-oncology
New York, 20 Dec. 10, 2022 (GLOBE NEWSWIRE) — Insilico Medicine (“Insilico”), an end-to-end clinical-stage artificial intelligence (AI)-focused drug discovery company, today announced that it has named ISM4312A in as a preclinical candidate targeting DGKA with an AI-identified target and an AI-designed structure for immuno-oncology therapeutics. This is another fully discovered and AI-engineered program that …